<DOC>
	<DOCNO>NCT00957372</DOCNO>
	<brief_summary>The primary objective evaluate efficacy eslicarbazepine acetate ( ESL ) administer daily 1200 mg 800 mg , compare placebo adjunctive therapy patient refractory partial epilepsy 12-week maintenance period .</brief_summary>
	<brief_title>Efficacy Safety Eslicarbazepine Acetate Adjunctive Therapy Refractory Partial Epilepsy</brief_title>
	<detailed_description>This phase III , 2-part multicenter study . Part I 26-week parallel-group , randomize , placebo-controlled design consist 8 week baseline period , 2 week double-blinded titration period , 12 week maintenance period , 4 week tapering-off period . After complete baseline period , patient randomize 1:1:1 ratio 1 2 ESL daily dose level ( 1200 800 mg ) placebo . Part II 1-year open-label extension patient complete Part I . Starting 800 mg/day , dosage could titrate 400 mg interval minimum 400 mg/day maximum 1200 mg/day . Patients complete Part II could participate study extension continue treatment ESL marketing authorization obtain clinical development discontinue , visit schedule discretion investigator least every 6 month . Results Part I &amp; II present two separate report .</detailed_description>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Epilepsies , Partial</mesh_term>
	<mesh_term>Eslicarbazepine acetate</mesh_term>
	<criteria>write informed consent sign patient age 18 year document diagnosis simple complex partial seizure without secondary generalisation since least 12 month prior screen least 4 partial seizure 4 week period last 8 week prior screen , currently treat 1 2 AEDs ( except oxcarbazepine felbamate ) , stable dose regimen least 2 month prior screen ( patient use vigabatrin medication least 1 year deficit visual field identify ) except epilepsy , patient judge general good health base medical history , physical examination laboratory test postmenopausal otherwise incapable become pregnant reason surgery tubal ligation ; case woman childbearing potential , patient must present serum betahCG test consistent nongravid state agree remain abstinent use reliable contraception ( oral contraception combine barrier method ) simple partial seizure motor symptomatology ( classified A24 accord International Classification Epileptic Seizures ) videoEEG document primarily generalise epilepsy know rapid progressive neurological disorder ; history status epilepticus cluster seizure ( i.e. , 3 seizure within 30 minute ) within 3 month prior screen seizure psychogenic origin within last 2 year history schizophrenia suicide attempt currently exposure felbamate oxcarbazepine within one month screen use benzodiazepine occasional basis ( except use chronically AED ) previous use ESL participation clinical study ESL know hypersensitivity carbamazepine , oxcarbazepine chemically related substance history abuse alcohol , drug medication within last 2 year uncontrolled cardiac , renal , hepatic , endocrine , gastrointestinal , metabolic , haematological oncology disorder second thirddegree atrioventricular blockade correct pacemaker relevant clinical laboratory abnormality</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>epilepsy</keyword>
</DOC>